BKA
SGMO

Brick & Kyle Associates’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Brick & Kyle Associates’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,100
Closed -$6K – 314
2017
Q1 		$6K Hold
1,100
– – ﹤0.01% 371
2016
Q4 		$3K Hold
1,100
– – ﹤0.01% 403
2016
Q3 		$5K Hold
1,100
– – ﹤0.01% 383
2016
Q2 		$6K Hold
1,100
– – ﹤0.01% 381
2016
Q1 		$7K Hold
1,100
– – 0.01% 367
2015
Q4 		$10K Hold
1,100
– – 0.01% 342
2015
Q3 		$6K Hold
1,100
– – 0.01% 380
2015
Q2 		$12K Hold
1,100
– – 0.01% 354
2015
Q1 		$17K Hold
1,100
– – 0.01% 305
2014
Q4 		$17K Buy
+1,100
New +$13.4K 0.01% 292

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Brick & Kyle Associates's SGMO Position: Q2 2017 in Review

Brick & Kyle Associates sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2017, closing a stake of 1,100 shares — an estimated $6K sold.

Brick & Kyle Associates first reported a position in SGMO in Q4 2014 and held it in 10 quarters. The position peaked at $17K in Q1 2015. 143 funds tracked by Wall St. Rank hold SGMO as of Q2 2017.

  • Brick & Kyle Associates reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2017 after selling out during the quarter.
  • Brick & Kyle Associates sold 1,100 SANGAMO THERAPEUTICS INC shares in Q2 2017, an estimated $6K.
  • Brick & Kyle Associates first reported a position in SANGAMO THERAPEUTICS INC in Q4 2014 and held it in 10 quarters.
  • Brick & Kyle Associates's SANGAMO THERAPEUTICS INC position peaked at $17K in Q1 2015.
  • 143 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2017.

Based on Brick & Kyle Associates's 13F filing for Q2 2017, filed 14 Aug 2017.